Article Versions Notes

Iwasaki-Hozumi H, Maeda Y, Niki T, Chagan-Yasutan H, Bai G, Matsuba T, Furushima D, Ashino Y, Hattori T. Plasma N-Cleaved Galectin-9 Is a Surrogate Marker for Determining the Severity of COVID-19 and Monitoring the Therapeutic Effects of Tocilizumab. International Journal of Molecular Sciences. 2023; 24(4):3591. https://doi.org/10.3390/ijms24043591

Iwasaki-Hozumi, Hiroko, Yosuke Maeda, Toshiro Niki, Haorile Chagan-Yasutan, Gaowa Bai, Takashi Matsuba, Daisuke Furushima, Yugo Ashino, and Toshio Hattori. 2023. "Plasma N-Cleaved Galectin-9 Is a Surrogate Marker for Determining the Severity of COVID-19 and Monitoring the Therapeutic Effects of Tocilizumab" International Journal of Molecular Sciences 24, no. 4: 3591. https://doi.org/10.3390/ijms24043591

Iwasaki-Hozumi, H., Maeda, Y., Niki, T., Chagan-Yasutan, H., Bai, G., Matsuba, T., Furushima, D., Ashino, Y., & Hattori, T. (2023). Plasma N-Cleaved Galectin-9 Is a Surrogate Marker for Determining the Severity of COVID-19 and Monitoring the Therapeutic Effects of Tocilizumab. International Journal of Molecular Sciences, 24(4), 3591. https://doi.org/10.3390/ijms24043591